These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6548688)

  • 21. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessing Drug Safety in Children - The Role of Real-World Data.
    McMahon AW; Dal Pan G
    N Engl J Med; 2018 Jun; 378(23):2155-2157. PubMed ID: 29874532
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 24. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 25. Post-marketing surveillance of prescription drug safety: past, present, and future.
    Chen BK; Yang YT
    J Leg Med; 2013; 34(2):193-213. PubMed ID: 23980746
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 27. The marketing of a drug.
    Wolfe SM
    Health Med; 1982; 1(2):31-2. PubMed ID: 10257087
    [No Abstract]   [Full Text] [Related]  

  • 28. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 29. Schroeder Lecture. Worst pills, best pills.
    Wolfe SM
    Health Matrix Clevel; 2006; 16(2):785-96. PubMed ID: 16948255
    [No Abstract]   [Full Text] [Related]  

  • 30. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 31. [Under FDA scrutiny: 19 drugs monitored for safety concerns].
    Sabourin G
    Perspect Infirm; 2010; 7(2):44-5. PubMed ID: 21744604
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 34. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 35. Report every adverse drug reaction! We're all in this together.
    Griffin GC; Parkinson RW; Woolley BH
    Postgrad Med; 1997 Apr; 101(4):13-6. PubMed ID: 9126202
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 37. Pilot projects to stimulate adverse drug reaction reporting.
    Fincham JE
    J Clin Pharm Ther; 1987 Aug; 12(4):243-7. PubMed ID: 3624325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 39. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 40. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.